EBMT 2018 | CMV treatment for stem cell transplant recipients: antivirals
Many infections can occur in cancer patients who are immunocompromised after receiving a stem cell transplant. In this interview, Genovefa Papanicolaou, MD, from Memorial Sloan Kettering Cancer Center, New York, NY, speaks about the current and future developments in the treatment of a particularly dangerous viral infection, cytomegalovirus (CMV). This interview was conducted at the 2018 European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal.
Get great new content delivered to your inboxSign up